Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Research studies have shown a strong association between cancer and blood clots in the veins
(also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary
embolism) which in severe cases may be life threatening. The purpose of this research study
is to see if enoxaparin is effective in preventing blood clots in the veins in participants
who have cancer of the pancreas, colorectal, non-small cell lung, ovary, or gastric and also
have high levels of tissue factor bearing microparticles in their blood (TFMP). TFMP are
small particles that are generated from different types of blood cells in the body. In people
who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk
factor for deep vein thrombosis. Enoxaparin has been used to prevent formation of blood clots
in patients after abdominal or orthopedic surgery and in patients who suffer from a severe
medical illness. Based on these studies, we are investigating to see if it prevents
thrombosis in people with certain types of cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Massachusetts General Hospital North Shore Medical Center Sanofi University of Southern California VA Boston Healthcare System